Immunomodulating Drugs for the Treatment of Cancer
Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology
| Author: | Asher A.A. Chanan-Khan | ISBN: | 9781451153613 |
| Publisher: | Wolters Kluwer Health | Publication: | March 29, 2012 |
| Imprint: | LWW | Language: | English |
| Author: | Asher A.A. Chanan-Khan |
| ISBN: | 9781451153613 |
| Publisher: | Wolters Kluwer Health |
| Publication: | March 29, 2012 |
| Imprint: | LWW |
| Language: | English |
Immunomodulating Drugs for the Treatment of Cancer provides a comprehensive resource for clinicians and researchers regarding immunomodulatory (IMiDs) drugs and their rapidly emerging role in cancer medicine. This new class of anticancer agents has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity.
Immunomodulating Drugs for the Treatment of Cancer provides a comprehensive resource for clinicians and researchers regarding immunomodulatory (IMiDs) drugs and their rapidly emerging role in cancer medicine. This new class of anticancer agents has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity.
